Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

What a difference five years can make. Just look at Eli Lilly(NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

Eli Lilly experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, sending shares in the US drugmaker up nearly 15 per cent in Wall Street ...

Eli Lilly (LLY) shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of ...